Lilly's Levatol (penbutolol)
Lilly's Levatol (penbutolol): Lilly is "continuing to assess marketing strategy "for the just-approved beta blocker licensed from Hoechst-Roussell ("The Pink Sheet, Jan. 4, p. 3). A Lilly spokesman said the company "has not determined when (Levatol) might be available." Lilly received approval for the one-a-day, non-cardioselective beta blocker on Dec. 31, nearly 4-1/2 years after NDA submission. Levatol is indicated for mild-to-moderate hypertension; recommeded dosage is two 10 mg tabs, once daily.
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.